---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-014063"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:55:54.266967+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows

## Summary
- Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).
- Gross margin 61.0% (down from 62.9%); net loss $7.7M ($0.11 per share) vs $7.4M ($0.12) last year.
- Adjusted EBITDA loss (incl legal) $4.5M, a $1.2M improvement from Q1 2021.
- Launched Tru Niagen Immune in April 2022; new TV campaign with encouraging early results.
- Granted U.S. continuation patent covering NR chloride, malate, and tartrate salts through 2037.

## SEC filing metadata
- accession: 0001628280-22-014063
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/0001628280-22-014063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/cdxc-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-014063
- JSON: https://secwatch.observer/filing/0001628280-22-014063.json
- Plain text: https://secwatch.observer/filing/0001628280-22-014063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.